JPS6033099B2 - Novel naphthylpropionate derivatives - Google Patents
Novel naphthylpropionate derivativesInfo
- Publication number
- JPS6033099B2 JPS6033099B2 JP15784976A JP15784976A JPS6033099B2 JP S6033099 B2 JPS6033099 B2 JP S6033099B2 JP 15784976 A JP15784976 A JP 15784976A JP 15784976 A JP15784976 A JP 15784976A JP S6033099 B2 JPS6033099 B2 JP S6033099B2
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- compound
- naphthyl
- general formula
- propionic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- FRXPDEZCWCPLIH-UHFFFAOYSA-N naphthalen-1-yl propanoate Chemical class C1=CC=C2C(OC(=O)CC)=CC=CC2=C1 FRXPDEZCWCPLIH-UHFFFAOYSA-N 0.000 title claims description 3
- 239000000126 substance Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 description 30
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 206010030113 Oedema Diseases 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- -1 naphthylpropionate ester Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N 2-(6-methoxy-2-naphthalenyl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QEHXDOJPVIHUDO-UHFFFAOYSA-N (2-fluorophenyl)methanol Chemical compound OCC1=CC=CC=C1F QEHXDOJPVIHUDO-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BASMANVIUSSIIM-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)benzene Chemical compound ClCC1=CC=CC=C1Cl BASMANVIUSSIIM-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001001462 Homo sapiens Importin subunit alpha-5 Proteins 0.000 description 1
- 102100036186 Importin subunit alpha-5 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Description
【発明の詳細な説明】
本発明は一般式
〔式中、Rは‘ィーハロゲン原子または低級アルキル基
で置換されたフェニル基、または【ローピリジル基を意
味する〕で表わされる新規なナフチルプロピオン酸ェス
テル誘導体に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel naphthylpropionate ester derivatives represented by the general formula [wherein R means a phenyl group substituted with a halogen atom or a lower alkyl group, or [a low pyridyl group]] It is related to.
前記一般式(1)で表わされる本発明の化合物は文献未
戦の新規化合物であり、顕著な鍵補作用、抗炎症作用及
び解熱作用等の薬理作用を有し医薬品として産業上有用
な化合物である。前記一般式(1)における置換基Rに
ついて更に具体的に説明すると、Rは、塩素、臭素、沃
素、鞠素等のハロゲン原子またはメチル、エチル、プロ
ピル、ブチル等の低級ァルキル基で置換されたフェニル
基を意味し、ピリジル基は2ーピリジル基、3−ピリジ
ル基、4ーピリジル基を表わす。The compound of the present invention represented by the general formula (1) is a novel compound that has not yet been published in the literature, and is an industrially useful compound as a pharmaceutical having significant pharmacological effects such as key synergistic effect, anti-inflammatory effect, and antipyretic effect. be. To explain more specifically the substituent R in the general formula (1), R is substituted with a halogen atom such as chlorine, bromine, iodine, or marmine, or a lower alkyl group such as methyl, ethyl, propyl, butyl. It means a phenyl group, and the pyridyl group represents a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group.
従来、外用消炎剤としては副腎皮質ホルモン製剤が大部
分を占めている。Conventionally, most topical anti-inflammatory agents have been adrenocortical hormone preparations.
しかし、ステロイド製剤は長期連用すると外用でも重纂
な副作用を発現するため、副作用の少ない非ステロイド
系外用消炎剤の開発が望まれているのが現状である。そ
こで本発明考等は非ステロイド系の新規化合物を求めて
鋭意研究を重ねた結果、前記一般式(1)で表わされる
ナフチルプロピオン酸ェステル誘導体が経口投与及び局
所適用において顕著な鎮痛作用及び抗炎症作用を有し、
且つ経口投与で胃腸管における副作用が少なく、内服薬
としても有用であることを見出し本発明を完成したので
ある。次に本発明に係る化合物の製造法に就いて述べる
。本発明の化合物は下記に記載する方法によって収率よ
く得ることが出来るがこれらの製造法は一例にすぎず当
然他の化学的類似方法によって製造出来るものである。
製造法A
一般式(oa)
で表わされる化合物及びその反応性誘導体に一般式(m
)RCH20日 (m)〔式中、R
は前記と同じ意味を有する〕で表わされるアルコールを
反応させる方法、製造法B
一般式(ロb)
〔式中、Mはアルカリ金属を意味する〕で表わされる化
合物に一般式(W)RCH2×
(W)〔式中、Xはハロゲン原子又は有機スルホニルオ
キシ基を、Rは前記と同じ意味を有する〕で表わされる
化合物を反応させる方法、製造法C
一般式(ロc)
〔式中、R′は低級アルキル基を意味する〕で表わされ
る化合物に一般式(m)で表わされるアルコールを反応
させ、ェステル交換させる方法、等が挙げられる。However, steroid preparations, when used externally for a long period of time, exhibit severe side effects, so there is currently a desire for the development of non-steroidal external anti-inflammatory agents with fewer side effects. Therefore, as a result of extensive research in search of a new non-steroidal compound, the present inventors found that the naphthylpropionate derivative represented by the general formula (1) has a remarkable analgesic effect and anti-inflammatory effect when administered orally and locally. has an effect,
Furthermore, they discovered that oral administration causes fewer side effects in the gastrointestinal tract, and that it is also useful as an internal medicine, thereby completing the present invention. Next, a method for producing the compound according to the present invention will be described. The compounds of the present invention can be obtained in good yields by the methods described below, but these manufacturing methods are merely examples, and of course they can be manufactured by other chemically similar methods.
Production method A A compound represented by the general formula (oa) and its reactive derivative is added to the compound represented by the general formula (m
) RCH 20th (m) [In the formula, R
has the same meaning as above], production method B A method of reacting an alcohol represented by the general formula (b) [wherein M means an alkali metal] with a compound represented by the general formula (W) RCH2×
(W) A method of reacting a compound represented by [wherein, ' means a lower alkyl group] is reacted with an alcohol represented by the general formula (m) to carry out transesterification.
次に本発明の実施方法を更に具体的に説明する。Next, the method of implementing the present invention will be explained in more detail.
製造法Aは2一(6ーメトキシ−2−ナフチル〕プロピ
オン酸(Ua)及びその反応性誘導体(例えば酸ハラィ
ド、酸無水物等)にアルコール類を反応させることによ
って行なわれる。Production method A is carried out by reacting 2-(6-methoxy-2-naphthyl)propionic acid (Ua) and its reactive derivatives (eg, acid halide, acid anhydride, etc.) with an alcohol.
化合物(ロa)とアルコール類(m)の反応は硫酸、ポ
リリン酸、p−トルェンスルホン酸等の脱水剤の存在下
、ベンゼン、トルェン、キシレン等の有機溶媒中、還流
下に反応させるか又は使用するアルコールが安価の場合
は溶媒を兼ねて反応させればよい。(oa)の反応性誘
導体として酸無水物を使用する時は、化合物(m)を3
〜10モル過剰に使用し少量の酸の存在下に加熱すれば
よい。又、酸ハラィドを使用する場合は脱酸剤(例えば
ピリジン、トリメチルアミン、トリェチルアミン等)の
存在下テトラヒドロフラン、ジグリム、アセトン、クロ
ロホルム、ベンゼン、トルェン等の反応に関与しない有
機溶媒中で冷却下又は室温で反応させればよい。製造法
Bは一般式(ob)で表わされる金属塩に一般式(W)
で表わされる化合物をテトラヒドロフラン、ジグリム、
ジオキサン、アセトン、クロロホルム、ベンゼン、トル
エン、キシレン、ジメチルホルムアミド等の有機溶媒中
で加熱すればよい。The reaction between compound (roa) and alcohol (m) can be carried out under reflux in the presence of a dehydrating agent such as sulfuric acid, polyphosphoric acid, or p-toluenesulfonic acid, in an organic solvent such as benzene, toluene, or xylene. Alternatively, if the alcohol used is inexpensive, it may be used as a solvent for the reaction. When using an acid anhydride as a reactive derivative of (oa), compound (m) is
It may be used in an excess of ~10 moles and heated in the presence of a small amount of acid. In addition, when using an acid halide, in the presence of a deoxidizing agent (for example, pyridine, trimethylamine, triethylamine, etc.), in an organic solvent that does not participate in the reaction, such as tetrahydrofuran, diglyme, acetone, chloroform, benzene, toluene, etc., under cooling or at room temperature. All you have to do is react. Production method B involves adding general formula (W) to a metal salt represented by general formula (ob).
Compounds represented by tetrahydrofuran, diglyme,
It may be heated in an organic solvent such as dioxane, acetone, chloroform, benzene, toluene, xylene, or dimethylformamide.
製造法Cは一般式(oc)で表わされる化合物に一般式
(m)で表わされるアルコールを過剰モル使用し、直接
又は少量のアルカリ金属の存在下に加熱すればすみやか
にェステル交換反応が進行する。Production method C uses an excess molar amount of the alcohol represented by the general formula (m) in the compound represented by the general formula (oc), and when heated directly or in the presence of a small amount of alkali metal, the transesterification reaction proceeds quickly. .
次に、本発明の化合物に関する薬理実験結果を示す。Next, the results of pharmacological experiments regarding the compounds of the present invention will be shown.
実験例 1
ラットでのカラゲニン足浮腫抑制作用試験(実験方法)
:体重140〜150夕のWistar系雄性ラツトを
1群5匹として、1錨時間給食後、試験化合物を経口授
与1時間後に、ラットの足藤に1%カラゲニン水溶液0
.1私を皮下注射した。Experimental example 1 Carrageenin paw edema suppression effect test in rats (experimental method)
: Groups of 5 male Wistar rats weighing 140-150 mm were fed for 1 hour, and 1 hour after oral administration of the test compound, a 1% aqueous carrageenan solution was applied to the rats' paw pads.
.. 1 I was injected subcutaneously.
趣炎剤注射3時間後に、足容積を測定し、下記の式より
足浮腫率および浮腫抑制率を求めた。なお、試験化合物
は、0.5%トラガントゴム水溶液に懸濁し、対照群に
は溶媒のみを投与した。浮腫率(%)=カラゲニン注射
後足容積−カラゲニン注射前足容積XI。Three hours after the injection of the antiinflammatory agent, the paw volume was measured, and the paw edema rate and edema suppression rate were calculated from the following formula. The test compound was suspended in a 0.5% aqueous solution of gum tragacanth, and only the solvent was administered to the control group. Edema rate (%) = carrageenin injection hind paw volume - carrageenin injection paw volume XI.
〇カラゲニン注射前足容積浮腫抑制率(%)= 対照群の浮腫率−薬物処置群の浮腫率 対照群の浮腫率 実験結果を表1に示す。〇Carrageenin injection paw volume edema suppression rate (%) = Edema rate of control group - Edema rate of drug treated group Edema rate in control group The experimental results are shown in Table 1.
(実験に用いた化合物)
{1)〔2一(6ーメトキシ−2−ナフチル)プロピオ
ン酸−Pーメチルベンジンェステル〕……以下、実施例
Aの化合物という。(Compounds used in the experiment) {1) [2-(6-methoxy-2-naphthyl)propionic acid-P-methylbenzine ester]...Hereinafter, referred to as the compound of Example A.
‘2’〔2一(6−メトキシー2ーナフチル)プロピオ
ン酸−4ーピリジルメチルェステル〕・・・・・・以下
、実施例Bの化合物という。'2' [2-(6-methoxy-2-naphthyl)propionic acid-4-pyridylmethyl ester]...Hereinafter, referred to as the compound of Example B.
【3’〔2−(6ーメトキシ−2ーナフチル)プロピオ
ン酸−m‐フルオロベンジンェステル〕…・・・以下、
実施例Cの化合物という。[3'[2-(6-methoxy-2naphthyl)propionic acid-m-fluorobenzine ester]...Hereinafter,
It is referred to as the compound of Example C.
‘41(6−メトキシー2ーナフチルー2メテル酢酸メ
チル)・・・・・・以下、比較化合物という。'41 (6-methoxy-2-naphthyl-2-methyl acetate)...hereinafter referred to as a comparative compound.
表1.ラットでのヵラゲニン足浮腫抑制作用試験**:
危険率1%で対照群に比較して浮腫率にて有意差がある
ことを示す。実施例 2
ラットでの異漬傷惹起作用試験
体重170〜180夕のWistar系雄性ラットを1
群7匹として、2岬時間絶食後、試験化合物を経口経与
3.虫時間後にラットを放皿致死させ、胃を摘出した。Table 1. Carrageenin paw edema suppression effect test in rats**:
It shows that there is a significant difference in edema rate compared to the control group at a risk rate of 1%. Example 2 Test of inducing effect on different pressure injuries in rats Male Wistar rats weighing 170-180 kg were
After fasting for 2 hours, the test compound was administered orally to 7 animals in a group.3. After several hours, the rats were sacrificed by plating and their stomachs were removed.
1%ホルマリン液low‘を胃内に注入、固定後、胃を
切開し、ェロジオンの有無を観察した。なお、試験化合
物は0.5%トラガントガム水溶液に懸濁し、対照群に
は溶媒のみを投与した。実験結果を表2に示す。尚、実
施例A、B、Cの各化合物及び比較化合物とは実験例1
で用いた化合物と同一のものを示す。After injecting 1% formalin solution LOW' into the stomach and fixing it, the stomach was incised and the presence or absence of erodion was observed. The test compound was suspended in a 0.5% gum tragacanth aqueous solution, and only the solvent was administered to the control group. The experimental results are shown in Table 2. The compounds of Examples A, B, and C and the comparative compounds are Experimental Example 1.
The same compound as used in is shown.
表2 ラソトでの胃債場惹起作用試験
以上の実験例1および2の実験結果より、本願発明の化
合物は顕著な抗炎症作用を有し、しかも非ステロイド抗
炎症剤に多く発生する胃潰湯がほとんど見られず、非常
に副作用が緩和された安全性の高い薬物であることが判
明した。Table 2 Test for inducing effect on stomach irritation in Rasotho From the experimental results of Experimental Examples 1 and 2 above, it is clear that the compound of the present invention has a remarkable anti-inflammatory effect, and gastric ulcer is more common in non-steroidal anti-inflammatory drugs. This drug was found to be a highly safe drug with very few side effects.
以下に実施例を示し、本発明を具体的に説明するが勿論
本発明はこれら実施例中の化合物のみ限定されるもので
はない。EXAMPLES The present invention will be specifically explained below with reference to Examples, but it goes without saying that the present invention is not limited only to the compounds in these Examples.
実施例 1
2−(6ーメトキシ−2ーナフチル)プロピオン酸2.
3夕と塩化チオニル3.6夕と無水ベンゼン30机の混
合物を3時間加熱還流した。Example 1 2-(6-methoxy-2-naphthyl)propionic acid2.
A mixture of 3.6 parts of thionyl chloride and 30 parts of anhydrous benzene was heated under reflux for 3 hours.
反応終了後、過剰の塩化チオニルとベンゼンを減圧下に
蟹去して得られる油状物を無水テトラヒドロフラン40
舷に溶かしo−フルオロベンジルアルコール1.5夕を
加えた。氷冷下にトリェチルアミン2私を加えた後、室
温で30分間縄拝した。反応終了後、テトラヒドロフラ
ンを減圧下に留去し、残澄に水を加えて得られた油状物
質を塩化メチレンで抽出し無水硫酸マグネシウムで脱水
後、溶媒を蟹去し得られた物質をエーテルと石油エーテ
ルの混合溶媒から再結晶して、無色針状晶の2一(6ー
メトキシー2ーナフチル)プロピオン酸一o一フルオロ
べンジルェステル2.7夕を得た。この物質の融点及び
元素分析値は次の通りであった。After the reaction, excess thionyl chloride and benzene were removed under reduced pressure, and the resulting oil was dissolved in anhydrous tetrahydrofuran (40 mL).
1.5 liters of dissolved o-fluorobenzyl alcohol was added to the gunwale. After adding 2 parts of triethylamine while cooling on ice, the mixture was incubated at room temperature for 30 minutes. After the reaction was completed, tetrahydrofuran was distilled off under reduced pressure, water was added to the residue, the resulting oily substance was extracted with methylene chloride, dried over anhydrous magnesium sulfate, the solvent was removed, and the resulting substance was diluted with ether. Recrystallization from a mixed solvent of petroleum ether gave colorless needle-like crystals of monofluorobenzyl 2-(6-methoxy-2-naphthyl)propionic acid ester. The melting point and elemental analysis values of this substance were as follows.
融点 72〜74℃
元素分析値 C2,日,8F03
理論値 C:74.離 日:5.66
実測値 C:74.15 H:5.52実施例 2
2一(6−メトキシー2ーナフチル)プロビオン酸2.
3夕をジメチルホルムアミド30地に溶かし50%水素
化ナトリウム0.6夕を加え室温で30分間燈拝した。Melting point 72-74°C Elemental analysis value C2, day, 8F03 Theoretical value C:74. Separation date: 5.66 Actual value C: 74.15 H: 5.52 Example 2 2-(6-methoxy-2-naphthyl)probionic acid 2.
The solution was dissolved in 30% dimethylformamide, 0.6% 50% sodium hydride was added, and the mixture was lit for 30 minutes at room temperature.
次にo−クロロベンジルクロラィド3.2夕を加えて2
時間10000で加熱した。反応終了後、溶媒を減圧下
に留去し、残澄に水を加えて得られた油状物質を塩化メ
チレンで抽出し無水硫酸マグネシウムで脱水後、溶媒を
蟹去し得られた物質をエーテルと石油エーテルの混合溶
媒から再結晶して、無色針状晶の2−(6−メトキシ−
2−ナフチル)プロピオン酸−o−クロロベンンジルェ
ステル2.8夕を得た。この物質の融点及び元素分析値
は次の通りであつた。Next, add 3.2 hours of o-chlorobenzyl chloride and
Heated for 10,000 hours. After the reaction, the solvent was distilled off under reduced pressure, water was added to the residue, the resulting oily substance was extracted with methylene chloride, dried over anhydrous magnesium sulfate, the solvent was evaporated, and the resulting substance was diluted with ether. Recrystallization from a mixed solvent of petroleum ether gave colorless needle-like crystals of 2-(6-methoxy-
2.8 hours of 2-naphthyl)propionic acid-o-chlorobenzyl ester were obtained. The melting point and elemental analysis values of this substance were as follows.
融点 79〜80℃
元素分析値 C2,日,9CI03
理論値 C:71.雌 H:5.40
実測値 C:70.89 H:5.32以下、実施例
1〜2の方法に準じて下記の化合物を合成した。Melting point 79-80°C Elemental analysis value C2, day, 9CI03 Theoretical value C:71. Female H: 5.40 Actual value C: 70.89 H: 5.32 The following compounds were synthesized according to the methods of Examples 1 and 2.
2一(6−メトキシー2ーナフチル)プロピオン酸−2
−ピリジルメチルェステル融点 88〜892一(6ー
メトキシ−2−ナフチル)プロピオン酸−3ーピリジル
メチルェステル融点 鼠〜6げ0
2一(6−メトキシ−2−ナフチル)プロピオン酸−4
−ピリジルメチルェステル融点 76〜7軌○
2一(6−メトキシ−2ーナフチル)プロピオン酸−m
ークロロベンジルェステル樹上点 43〜45℃
2−(6ーメトキシ−2ーナフチル)プロピオン酸−p
ーク。2-(6-methoxy-2-naphthyl)propionic acid-2
-Pyridylmethyl ester melting point 88-892-(6-methoxy-2-naphthyl)propionic acid-3-pyridylmethyl ester melting point 6-60 2-(6-methoxy-2-naphthyl)propionic acid-4
-Pyridyl methyl ester melting point 76-7 orbit○ 2-(6-methoxy-2-naphthyl)propionic acid-m
-Chlorobenzyl ester tree point 43-45℃ 2-(6-methoxy-2naphthyl)propionic acid-p
-k.
ロベンジルェステル融点 78〜8ぴ○
2一(6−メトキシー2ーナフチル)ブロピオン酸−m
−フルオロベンジルェステル繭虫点 35〜370
2一(6−メトキシー2ーナフチル)プロピオン酸−p
ーフルオロベンジルェステル融点 61〜6多○
2一(6−メトキシー2−ナフチル)プロピオン酸−o
ーメチルベンジルェステル鷲&点 79〜81℃
2一(6−メトキシ−2−ナフチル)ブロピオン酸−m
−メチルベンジルヱステル融点 45〜46℃
2一(6−メトキシー2ーナフチル)プロピオン酸−p
ーメチルベンジルェステル図虫点 89〜90℃Lobenzyl ester melting point 78-8 pi○ 2-(6-methoxy-2-naphthyl)propionic acid-m
-Fluorobenzyster cocoon point 35-370 2-(6-methoxy-2-naphthyl)propionic acid-p
-Fluorobenzyl ester melting point 61-6 poly○ 2-(6-methoxy-2-naphthyl)propionic acid-o
-Methyl benzyl ester eagle & point 79-81℃ 2-(6-methoxy-2-naphthyl)bropionic acid-m
-Methylbenzylester Melting point 45-46℃ 2-(6-methoxy-2-naphthyl)propionic acid-p
- Methylbenzyl ester figure insect point 89-90℃
Claims (1)
で置換されたフエニル基、または(ロ)ピリジル基を意
味する)で表わされるナフチルプロピオン酸エステル誘
導体。[Claims] 1 General formula ▲ Numerical formula, chemical formula, table, etc. ▼ (In the formula, R means (a) a phenyl group substituted with a halogen atom or a lower alkyl group, or (b) a pyridyl group) ) A naphthylpropionate derivative represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15784976A JPS6033099B2 (en) | 1976-12-27 | 1976-12-27 | Novel naphthylpropionate derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15784976A JPS6033099B2 (en) | 1976-12-27 | 1976-12-27 | Novel naphthylpropionate derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5382761A JPS5382761A (en) | 1978-07-21 |
| JPS6033099B2 true JPS6033099B2 (en) | 1985-08-01 |
Family
ID=15658696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15784976A Expired JPS6033099B2 (en) | 1976-12-27 | 1976-12-27 | Novel naphthylpropionate derivatives |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6033099B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1209145B (en) * | 1979-11-23 | 1989-07-10 | Resfar Srl | PROCEDURE TO IMPROVE THE PHARMACOLOGICAL CHARACTERISTICS OF ARIL-ALCANOIC ACIDS ANALGESIC AND ANTI-INFLAMMATORY ADAPTITY. |
| US4912248A (en) * | 1987-05-18 | 1990-03-27 | The Procter & Gamble Company | Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation |
-
1976
- 1976-12-27 JP JP15784976A patent/JPS6033099B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5382761A (en) | 1978-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0028834B1 (en) | Imidazole-5-acetic acid derivatives, their production and use | |
| US4752613A (en) | Sulphonamidothienylcarboxylic acid compounds | |
| US3678077A (en) | 9-oxoxanthen-2-yl-alkanoic acids | |
| US3780061A (en) | Tricyclic ketonic compounds | |
| US4165428A (en) | Indoleacetic acid ester derivatives | |
| EP0074170B1 (en) | Chroman compounds, process for producing them and pharmaceutical compositions containing them | |
| JPS6033099B2 (en) | Novel naphthylpropionate derivatives | |
| US4118504A (en) | Isoindoline derivatives for treating pain | |
| JPS5967292A (en) | Thiazine derivative | |
| US4233304A (en) | Pyridoxine derivatives | |
| CH628014A5 (en) | Gamma-aryl-gamma-oxoisovaleric acids having antiphlogistic and antalgic properties | |
| US4230719A (en) | Novel 2-[4-(3-methyl-2-thienyl)phenyl]propionic acid and pharmaceutically acceptable salt thereof and method for treating symptoms of inflammation and pain | |
| JPS604809B2 (en) | Novel 2-(m-benzoyl)phenylpropionate derivative | |
| JPH0625151B2 (en) | 2-Substituted cycloheptoimidazole derivative, antiulcer agent and method for producing the same | |
| CS216205B2 (en) | Method of making the derivatives of the 1,4-diphenylpyrazole | |
| JPS6019317B2 (en) | Thienothiazine derivative and method for producing the same | |
| NO743135L (en) | ||
| US3564008A (en) | Process for preparing 1-acyl-2-phenyl-3-indolylaliphatic acid derivatives | |
| US4122091A (en) | Cyclopenta[B]thiophene derivatives | |
| US4128550A (en) | 1-Methyl-4-piperidyl 5-phenyl-2-furoates | |
| CA1122601A (en) | 4-(2'-pyridylamino)phenylacetic acid derivatives | |
| JPS6039064B2 (en) | Novel phenyl acetate derivative | |
| IL34468A (en) | Acid addition salts of indenopyridine derivatives,their preparation and pharmaceutical compositions containing them | |
| KR920006785B1 (en) | 1-heteroaryl-3-acyl-2-oxindole anti-inflammatory | |
| US4156000A (en) | Cyclopenta[b]thiophene derivatives |